---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-016474"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:50:07.089235+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics issues $937.5k convertible note, dismisses auditor Wolf & Co., appoints Eric Francois to board

## Summary
- Issued $937,500 convertible note to Keystone Capital Partners at $750,000; 10% interest, matures July 2027, convertible at discount to market.
- Dismissed Wolf & Company, P.C. as auditor effective Feb 13, 2026; no disagreements, but prior material weakness in internal controls noted.
- Appointed Salberg & Company, P.A. as new auditor effective Feb 13, 2026.
- Appointed Eric Francois to board, increasing size to 7; he served as Managing Director at Raymond James, CFO at Scynexis.

## SEC filing metadata
- accession: 0001213900-26-016474
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 4.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/ea0276984-8k_ceroa.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-016474
- JSON: https://secwatch.observer/filing/0001213900-26-016474.json
- Plain text: https://secwatch.observer/filing/0001213900-26-016474.txt

## Key facts
- Auditor Changes
  CERO THERAPEUTICS HOLDINGS, INC. dismissed Wolf & Company, P.C. as its auditor.
  - Action: dismissal
  - Auditor: Wolf & Company, P.C.
  - Successor: Salberg & Company, P.A.
  source text: The Company’s audit committee of the board of directors (the “Audit Committee”) approved the decision to dismiss Wolf & Company, P.C. (“Wolf”), as the Company’s independent registered public accounting firm, effective as of February 13, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm
- Auditor Changes
  CERO THERAPEUTICS HOLDINGS, INC. engaged Salberg & Company, P.A. as its auditor.
  - Action: engagement
  - Auditor: Salberg & Company, P.A.
  source text: The Company’s audit committee of the board of directors (the “Audit Committee”) approved the appointment of Salberg & Company, P.A. (“Salberg”) as the Company’s independent registered public accounting firm, effective following the finalization of the terms of an engagement letter therewith and execution thereof of February 11, 2026, with such appointment effective as of February 13, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm
- Debt Financings
  CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $750,000 with Keystone Capital Partners, LLC at 10% per annum maturing July 9, 2027.
  - Instrument: convertible notes
  - Principal: $750,000
  - Counterparty: Keystone Capital Partners, LLC
  - Rate: 10% per annum
  - Maturity: July 9, 2027
  - Event: incurrence
  source text: On February 9, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm
- Equity Issuances
  CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for $750,000.
  - Security: convertible note
  - Purchaser: Keystone Capital Partners, LLC
  - Consideration: $750,000
  source text: On February 9, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. entered into Note with Keystone Capital Partners, LLC valued at $750,000 (effective 2026-02-09).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: Keystone Capital Partners, LLC
  - Value: $750,000
  - Effective: 2026-02-09
  source text: On February 9, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.